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A survey of physician receptivity to
molecular diagnostic testing and readiness
to act on results for early-stage colon
cancer patients
Ronald E. Myers1* , Thomas Wolf1, Phillip Shwae2, Sarah Hegarty3, Stephen C. Peiper4 and Scott A. Waldman3
Abstract
Background: We sought to assess physician interest in molecular prognosic testing for patients with early stage
colon cancer, and identify factors associated with the likelihood of test adoption.
Methods: We identified physicians who care for patients with early-stage (pN0) colon cancer patients, mailed them
a survey, and analyzed survey responses to assess clinician receptivity to the use of a new molecular test (GUCY2C)
that identifies patients at risk for recurrence, and clinician readiness to act on abnormal test results.
Results: Of 104 eligible potential respondents, 41 completed and returned the survey. Among responding physicians,
56 % were receptive to using the new prognostic test. Multivariable analyses showed that physicians in academic
medical centers were significantly more receptive to molecular test use than those in non-academic settings.
Forty-one percent of respondents were ready to act on abnormal molecular test results. Physicians who viewed current
staging methods as inaccurate and were confident in their capacity to incorporate molecular testing in practice were
more likely to say they would act on abnormal test results.
Conclusions: Physician receptivity to molecular diagnostic testing for early-stage colon cancer patients is likely to be
influenced by practice setting and perceptions related to delivering quality care to patients.
Trial registration: ClinicalTrials.gov Identifier: NCT01972737
Keywords: Decision analysis, Cancer, Colon carcinogenesis, Molecular genetics, Staging
Background
Advances in identifying novel markers and related clinical
targets, along with the emergence of new diagnostic tech-
niques and the development of pharmacologic antagonists
of key signaling elements have generated expectations of
dramatic change in the care of patients diagnosed with
cancer. New and emerging molecular diagnostic tests have
the potential to improve the accuracy of disease staging,
determine if a given patient may be predisposed to disease
progression, and provide useful information about the
patient’s likely response to treatment.
In the age of personalized medicine, patients are be-
coming increasingly aware of and are asking physicians
about the value of such testing. Physicians who care for
cancer patients are challenged by the need to learn
about new developments in the field and the demand to
apply these new tools in patient care [1]. Realizing the
potential benefits of molecular diagnostic testing in can-
cer care will require high levels of physician receptivity
and readiness to use such tests routinely [2, 3]. To date,
however, limited research has reported on physician
receptivity to and use of molecular diagnostic testing in
cancer care [4].
In a recent survey, 75 % of physicians who treat cancer
patients said they believe the use of genomic testing can
improve patient care. However, respondents also stated
that they had ordered genomic testing for only 4 % of
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their patients [5]. In another study, 90 % of respondents
reported that they supported genomic testing, but less
than half felt confident in their ability to interpret the
test results to their patients [6]. Similar findings were
noted by Stanek et al. [7] who found that 98 % of physi-
cians surveyed viewed molecular risk assessment as
having the potential to play a crucial role in determining
drug therapies for patients, but only 10 % felt confident
in their understanding to best use test results to guide
the process of prescribing treatment.
The study reported here focuses on guanylate cyclase
C (GUCY2C) testing, a new molecular diagnostic test
that has been developed for use in conjunction with
histopathology to guide treatment decision making for
patients with early-stage (pN0) colon cancer. Conven-
tional histopathological analysis for such patients is rou-
tinely triggered at the time of diagnosis (“reflex tests”),
and therapy is to a large degree based on the pathologic
stage that is determined. GUCY2C is a protein expressed
normally by intestinal epithelial cells, but is universally
over-expressed by metastatic colon tumors [8–10]. There
is a strong association between the expression of
GUCY2C in regional lymph nodes, measured using a vali-
dated quantitative RT-PCR assay [11], and the develop-
ment of recurrent metastatic disease in otherwise lymph
node-negative patients [12, 13]. Moreover, this test has
been externally validated and commercialized [14–17].
The current investigation was part of a larger clinical
trial (NCT01972737), which focused on the utility of
GUCY2C as a vaccine target for the secondary preven-
tion of metastatic colorectal cancer. Here, we collected
and analyzed survey data from clinicians in the Greater
Philadelphia Area who treat colon cancer patients. Main
objectives were to: (1) assess physician receptivity to
GUCY2C testing, (2) assess physician readiness to act on
test results, and (3) identify factors associated with test
receptivity and readiness to act.
Methods
The research team initially obtained from the Depart-
ment of Strategy and Business Development at Thomas
Jefferson University a mailing list of medical oncologists,
surgeons, and gastroenterologists practicing in the Greater
Philadelphia Area. Following established methods [18], we
sent all physicians on the mailing list an introductory letter
that described the purpose of the study and invited
response via provision of written consent. In addition, we
requested that recipients of the invitation complete and
return an enclosed survey questionnaire using a postage-
paid return envelope or to complete an online version of
the survey. The mailing also advised the recipient that s/he
would be compensated ($125) for completion of the survey.
We also included a postcard in the mailing that allowed the
recipient to opt-out of the study. A month after this initial
mailing, the research team sent non-respondents another
study invitation, which included a copy of the survey ques-
tionnaire, an opt-out card, and a return envelope. At
60 days, the research team attempted to contact non-
respondents by telephone to encourage response.
At the beginning of the survey, GUCY2C and testing
were described as follows: “GUCY2C is a protein
expressed normally by intestinal epithelial cells, but is
universally over-expressed by metastatic colon tumors.
There is a relationship between the categorical (yes/no)
presence of occult tumor cells in lymph nodes detected
by GUCY2C testing and prognosis in pN0 colon cancer.
This paradigm has been used to quantify occult tumor
burden in nodes. The GUCY2C test could be ordered
for colon cancer patients at the time of surgery. Results
of this test could be used in conjunction with histopath-
ology to inform the clinical decision to or not to recom-
mend chemotherapy.” Survey items that operationalized
constructs drawn from an explanatory framework
known as the Diagnostic Evaluation Model (DEM) [19]
followed this scenario.
DEM items measured factors that could help to ex-
plain physician receptivity to GUCY2C testing and
readiness to act on test results. These factors include
physician practice environment, sociodemographic back-
ground characteristics and experience, perceptions about
testing, and perceptions about treatment. Regarding
practice environment, respondents were asked whether
they practiced mainly in an academic medical center,
community-based hospital, and other practice settings.
We asked respondents to provide information on back-
ground characteristics (i.e., age, gender, race, ethnicity,
and years in practice) and experience caring for colon
cancer patients (i.e., exposure to pN0 colon cancer
patients and patients who experienced recurrence).
To elicit perceptions about testing, we asked respon-
dents to report how accurate they thought histopath-
ology, GUCY2C testing, and combined histopathology
and GUCY2C testing are in staging pN0 colon cancer
patients (i.e., not accurate, somewhat accurate, very
accurate). In addition, we asked whether physicians
agreed (Strongly Disagree – 1 versus Strongly Agree -
5) that each of these three approaches to testing could
provide sufficient information that was needed to rec-
ommend treatment. An item that assessed respondent
agreement with the view that current testing methods
were sufficiently accurate for pN0 colon cancer patients
was also included.
Respondent perceptions about treatment were mea-
sured by assessing physician stress from uncertainty
using five items from the Physicians’ Reactions to Uncer-
tainty (PRU) scale (α = 0.59) [20]. Single items were used
to measure physician perceived ease of making a treat-
ment decision for pN0 colon cancer patients, confidence
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in identifying an effective treatment for early-stage colon
cancer patients, and confidence that molecular diagnos-
tic testing could improve patient treatment.
We assessed physician interest in the new test along
two dimensions, receptivity and readiness to act. Specif-
ically, we determined physician receptivity to the test by
eliciting level of agreement (Strongly Disagree – 1 to
Strongly Agree - 5) with the following statements: “I
think GUCY2C test results should be considered when
treatment is recommended for pN0 colon cancer
patients.” and “I think all patients with pN0 colon cancer
should have a GUCY2C test.” The summed mean
responses to these items were dichotomized as <3 (dis-
agree or neutral) versus >3 (agree) to determine clinician
receptivity to the use of GUC2YC testing. Survey
respondents were determined to be receptive to testing
if the mean response to the two survey items was >3. In
terms of readiness to act, we asked physicians to
respond to the following statement: “I would treat
patients with pN0 colon cancer who have abnormal
GUCY2C test results more aggressively than patients
with a normal test result.” Responses were dichotomized
as ≤3 (disagree or neutral) versus >3 (agree)” to measure
clinician readiness to act on abnormal test results. Physi-
cians were considered to be ready to act on abnormal
test results if their response to this single item was >3.
Finally, we included open-ended questions that allowed
respondents to report factors that would influence them
to order GUCY2C testing.
Fisher’s Exact testing was used to assess statistically
significant associations between categorical variables and
the two outcomes, while the Wilcoxon test was used to
assess associations of continuous variables with out-
comes. Covariates associated with the outcome variables
at the p ≤ 0.2 level were included in a multivariable logis-
tic regression models. Backwards selection was used to
determine the model, with retention of those independ-
ent variables that were associated at p-value of 0.05.
Because of the small sample size, exact p-values are
reported.
Members of the research team (RM, TW, and PS)
reviewed comments reported by physicians on the
factors that would influence them to and not to order
testing, and generated a set of unique factor categor-
ies. Independently, TW and PS assigned each factor
to a category and then resolved any discrepancies in
joint consultation with RM. Category frequencies were
generated.
Results
A total of 211 physicians were targeted to receive the
mailed survey. Feedback from that initial mailing, a
subsequent reminder mailing, and a final telephone re-
minder resulted in the exclusion of 60 physicians with
incomplete contact information. Additionally, 47 indi-
viduals were excluded, because they reported that they
did not currently see pN0 colon cancer patients, and
two physicians were found to be deceased. Thus, there
were 104 physicians who were eligible and available to
complete the mailed survey. Of this number, 43 (41 %)
completed the survey, 18 (17 %) declined to participate,
and 43 (41 %) were lost to follow-up. The research team
decided to remove two gastroenterologists from the pool
of respondents because it was determined that physi-
cians in this specialty are unlikely to recommend
molecular testing for cancer patients following initial
diagnosis. Thus, 41 respondents were included in the
final analyses.
Survey DEM measures are displayed in Table 1. Study
outcomes displayed in Table 1 show that overall, 51 % of
respondents were <50 years of age; 83 % were male; and
68 % were white. Forty-nine percent of physicians agreed
that GUCY2C test results should be used to guide treat-
ment recommendations for patients with early-stage
colon cancer, and 44 % percent agreed that all early-
stage colon cancer patients should have such testing. A
total of 18 respondents had a two-item summed mean
response ≤3, and 22 respondents had a summed recep-
tivity score that was >3. The respective percentage of
respondents in these categories, which are not included
in the table, are 44 and 56 %, respectively. The numbers
of respondents in these categories corresponds to the
table column headings for the outcomes.
In univariable analyses (Table 1), the following
variables were associated with physician receptivity to
GUCY2C testing: practice located in an academic
medical center (p = 0.004); belief that the combined
results of histopathology and GUCY2C testing could
provide information needed to recommend treatment
(p = 0.038); belief that GUCY2C testing alone, as well as
combined histopathology and GUCY2C testing were
somewhat or very accurate (p = 0.133 and p = 0.054,
respectively); and belief that making treatment deci-
sions for pN0 colon cancer patients is easy (p = 0.009).
Multivariable analysis results (Table 2) indicate that
physicians who practiced in academic medical centers
were more receptive to GUCY2C testing than those
who practiced in community hospitals or other settings
(OR = 7.14, CI: 1.28, 55.02).
In terms of readiness to act (Table 3), there were 24
physicians had a response <3, while 17 clinicians who
had a response to the one item used to assess readiness
that was >3. The respective percentages of respondents
in these categories, which are not displayed in the table,
are 59 and 41 %, respectively. Univariable analyses
showed the following variables to be associated with
physician readiness to act on abnormal test results: race
(p = 0.103); belief that GUCY2C testing alone and the
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Table 1 Univariable associations of physician receptivity to genomic risk assessment (GUCY2C) for pN0 colon cancer patients
Total
(n = 41)
Receptive
(n = 22)
Not Receptive
(n = 19)
p-value
n (%) n (%) n (%)
Practice Environment:
Practice Setting 0.004
Community-based or Other 24 (58.54) 8 (33.33) 16 (66.67) .
Academic Center-based 17 (41.46) 14 (82.35) 3 (17.65) .
Sociodemographic Background and Experience:
Age 1.000
<50 21 (51.22) 11 (52.38) 10 (47.62) .
50+ 20 (48.78) 11 (55.00) 9 (45.00) .
Gender 0.219
Male 34 (82.93) 20 (58.82) 14 (41.18) .
Female 7 (17.07) 2 (28.57) 5 (71.43) .
Race 1.000
(missing/unknown) 1 (.) 0 (.) 1 (.) .
Asian 13 (32.50) 7 (53.85) 6 (46.15) .
White 27 (67.50) 15 (55.56) 12 (44.44) .
Hispanic/Latino 0.463
No 40 (97.56) 22 (55.00) 18 (45.00) .
Yes 1 (2.44) 1 (100.0) .
Years in Practice 0.891
< =10 4 (9.76) 2 (50.00) 2 (50.00) .
10–20 11 (26.83) 5 (45.45) 6 (54.55) .
>20 26 (63.41) 15 (57.69) 11 (42.31) .
Specialty 0.758
Medical Oncologists+ 23 (56.10) 13 (56.52) 10 (43.48) .
GI Surgeons 18 (43.90) 9 (50.00) 9 (50.00) .
Number of newly diagnosed pN0 colon cancer patients seen in past 12 months 0.668
<5 6 (14.63) 4 (66.67) 2 (33.33) .
5+ 35 (85.37) 18 (51.43) 17 (48.57) .
Percentage of pN0 colon cancer patients who have had a recurrence in the past 12 months 1.000
None 20 (48.78) 11 (55.00) 9 (45.00) .
1+ 21 (51.22) 11 (52.38) 10 (47.62) .
On average how many pN0 colon cancer patients do you see each month? 0.737
<5 28 (68.29) 16 (57.14) 12 (42.86) .
5+ 13 (31.71) 6 (46.15) 7 (53.85) .
Perceptions about Diagnostic/Prognostic Testing:
Belief in accuracy of histopathology 1.000
Not Agree 14 (34.15) 8 (57.14) 6 (42.86) .
Agree 27 (65.85) 14 (51.85) 13 (48.15) .
Belief in accuracy of GUY2C testing 0.216
Not Agree 17 (41.46) 7 (41.18) 10 (58.82) .
Agree 24 (58.54) 15 (62.50) 9 (37.50) .
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combined results of histopathology and GUCY2C testing
could provide information needed to recommend treat-
ment (p = 0.012 and p = 0.128, respectively); belief that
current staging methods are not accurate for pN0 colon
cancer patients (0.062); belief that GUCY2C testing alone,
as well as the combined results of histopathology and
Table 1 Univariable associations of physician receptivity to genomic risk assessment (GUCY2C) for pN0 colon cancer patients
(Continued)
Belief in accuracy of combined histopathology and GUCY2C testing 0.038
Not Agree 4 (9.76) 0 (0.0) 4 (100.0) .
Agree 37 (90.24) 22 (59.46) 15 (40.54) .
Belief in need for a more accurate prognostic test for pN0 colon cancer patients 1.000
Not Agree 2 (4.88) 1 (50.00) 1 (50.00) .
Agree 39 (95.12) 21 (53.85) 18 (46.15) .
Belief that current staging methods are not accurate for pN0 colon cancer patients 0.216
Not Agree 17 (41.46) 7 (41.18) 10 (58.82) .
Agree 24 (58.54) 15 (62.50) 9 (37.50) .
Accuracy of histopathology alone 0.388
(missing/unknown) 1 (.) 0 (.) 1 (.) .
Very Accurate 6 (15.00) 3 (50.00) 3 (50.00) .
Somewhat Accurate 31 (77.50) 16 (51.61) 15 (48.39) .
Not Accurate 3 (7.50) 3 (100.0) 0 (0.0) .
Don’t know 0 (0.0) 0 (0.0) 0 (0.0) .
Accuracy of GUCY2C testing alone 0.133
(missing/unknown) 2 (.) 0 (.) 2 (.) .
Very Accurate 6 (15.38) 4 (66.67) 2 (33.33) .
Somewhat Accurate 22 (56.41) 13 (59.09) 9 (40.91) .
Not Accurate 3 (7.69) 3 (100.0) 0 (0.0) .
Don’t Know 8 (20.51) 2 (25.00) 6 (75.00) .
Accuracy of combined histopathology and GUCY2C testing 0.054
(missing/unknown) 1 (.) 0 (.) 1 (.) .
Very Accurate 25 (62.50) 16 (64.00) 9 (36.00) .
Somewhat Accurate 11 (27.50) 6 (54.55) 5 (45.45) .
Not Accurate 0 (0.0) 0 (0.0) 0 (0.0)
Don’t Know 4 (10.00) 0 (0.0) 4 (100.0) .
Perceptions about Treatment:
Stress from uncertainty in decision making about treatment for pN0 colon cancer patients (scale) 0.350
Not Agree (<=3) 22 (53.66) 10 (45.45) 12 (54.55) .
Agree (>3) 19 (46.34) 12 (63.16) 7 (36.84) .
Belief that treatment decision making for pN0 colon cancer patients is easy 0.009
Not Agree 13 (31.71) 11 (84.62) 2 (15.38) .
Agree 28 (68.29) 11 (39.29) 17 (60.71) .
Confidence in treatment decision making for pN0 colon cancer patients 0.325
Not Agree 12 (29.27) 8 (66.67) 4 (33.33) .
Agree 29 (70.73) 14 (48.28) 15 (51.72) .
Belief that treatment choice for pN0 colon cancer patients is clear 0.756
Not Agree 19 (46.34) 11 (57.89) 8 (42.11) .
Agree 22 (53.66) 11 (50.00) 11 (50.00) .
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GUCY2C testing are somewhat or very accurate (p = 0.179
and p = 0.084, respectively); belief that treatment choice is
clear (p = 0.025).
Multivariable analysis results (Table 4) indicate that
physicians respondents who thought that current staging
methods for pN0 colon patients were not sufficiently
accurate were more likely to report that they would act
on abnormal GUCY2C test results than those who did
not hold this belief (OR = 5.98, CI: 1.05, 49.32). In
addition, physicians who stated that it was clear what
treatment choice is correct for their patients were
significantly more likely to say they would act on
GUY2C test results than those who were less confident
(OR = 7.74, CI: 1.41, 62.20).
All 41 physicians responded to the open-ended survey
question that asked them to indicate the factors that
would discourage them from recommending GUCY2C
testing. Together, the respondents identified a total of 85
factors. Of this number, 31 (36 %) factors related to hav-
ing insufficient information about test accuracy; 26
(31 %) expressed concern about the cost of such testing;
22 (26 %) said they were were not familiar with guide-
lines that specified circumstances for test use; and 9
(11 %) reported that they did not think the test was
readily available.
Discussion
This study is the first to measure physician interest in
molecular testing in terms of receptivity and readiness
to act on test results. In addition, the study is novel in
that it focuses attention on the testing for early-stage
colon cancer patients. Moreover, the study used an
explanatory framework (DEM) to identify factors that
influence physician receptivity to test use and readiness
to act on test results.
We found that 44 % of surveyed physicians were
receptive to GUCY2C testing for patients with early-
stage colon cancer. To our knowledge, this report is the
first instance in which physician receptivity to prognos-
tic molecular diagnostic testing in this patient popula-
tion been assessed. Elsewhere, it has been reported that
more than half of physicians who treat metastatic colo-
rectal cancer patients ordered a genetic test for their
patients after it was cited in clinical guidelines [2]. This
level of interest in molecular diagnostic testing suggests
that many physicians who treat early-stage patients see a
need to improve on existing staging methods, and have
a desire to consider test results in treatment planning.
We also determined that physicians who practiced at
academic medical centers were more enthusiastic about
molecular testing for risk of recurrence than their coun-
terparts in community hospital settings. This finding
may reflect the fact that molecular diagnostic testing is
more readily available in academic medical centers than
in community settings, as such testing can be provided
in-house. As a result, tests in academic settings can be
performed easily and their results obtained in a timely
manner to inform physician recommendations. It may
also be the case that there may be more opportunities
for physicians in academic medical centers to share
information about new molecular diagnostic tests,
personal experiences using the tests, and patient out-
comes. As a result, academic medical center-based
physicians may feel a greater sense confidence in using
the tests in routine care.
Forty-one percent of physicians in the current study
reported that they were ready to treat patients with an
abnormal GUYC2C test result more aggressively than
patients who had a normal test result. We found that
physicians who were ready to act on GUCY2C test
results were more likely to question the accuracy of
current staging methods than physicians who were not
ready to act of test results. Notably, 90 % of physicians
reported that the combined histopathology and molecu-
lar diagnostic testing could provide sufficient informa-
tion to allow them to make good treatment decisions.
Most physicians tended to view molecular diagnostic
testing as providing them with additional information
that, in conjunction with current histopathology results,
could help to better-forecast recurrence, and improve
their capacity to recommend the most appropriate treat-
ment. In the context of the current investigation, we
found that respondents who reported being ready to
treat patients with abnormal GUCY2C results more
aggressively were more likely to believe that molecular
testing could improve their capacity to provide high
quality care to their patients.
Physician readiness to act on abnormal test results
may be influenced to some extent by practitioner
feelings of stress from uncertainty about treating
early-stage colon cancer patients on the basis of
histopathology analyses alone, and confidence in
Table 2 Multivariable logistic regression on combined D1, D3 outcome (D1, D3 mean >3) (N = 41)
Exact odds ratios
Parameter Estimate 95 % Confidence limits Two-sided p-value
How would you describe your practice setting?
Hospital-based vs. Community Based/Other 7.14 1.28 55.02 0.021
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Table 3 Univariable associations of physician readiness to act on genomic risk assessment (GUCY2C) for pN0 colon cancer Patients
Variable Total
(n = 41)
Ready
(n = 17)
Not ready
(n = 24)
p-value
n (%) n (%) n (%)
Practice Environment:
Practice Setting 0.748
Community-based or Other 24 (58.54) 9 (37.50) 15 (62.50) .
Academic Center-based 17 (41.46) 8 (47.06) 9 (52.94) .
Sociodemographic Background and Experience:
Age 0.350
<50 21 (51.22) 7 (33.33) 14 (66.67) .
50+ 20 (48.78) 10 (50.00) 10 (50.00) .
Gender 1.000
Male 34 (82.93) 14 (41.18) 20 (58.82) .
Female 7 (17.07) 3 (42.86) 4 (57.14) .
Race 0.103
(missing/unknown) 1 (.) 1 (.) .
Asian 13 (32.50) 3 (23.08) 10 (76.92) .
White 27 (67.50) 14 (51.85) 13 (48.15) .
Hispanic/Latino 1.000
No 40 (97.56) 17 (42.50) 23 (57.50) .
Yes 1 (2.44) 1 (100.0) .
Years in Practice 0.559
< =10 4 (9.76) 2 (50.00) 2 (50.00) .
10–20 11 (26.83) 3 (27.27) 8 (72.73) .
>20 26 (63.41) 12 (46.15) 14 (53.85) .
Specialty 1.000
Medical Oncologists+ 23 (56.10) 10 (43.48) 13 (56.52) .
GI Surgeons 18 (43.90) 7 (38.89) 11 (61.11) .
Number of newly diagnosed pN0 colon cancer patients seen in past 12 months 0.679
<5 6 (14.63) 3 (50.00) 3 (50.00) .
5+ 35 (85.37) 14 (40.00) 21 (60.00) .
Percentage of pN0 colon cancer patients who have had a recurrence in the past 12 months 0.530
None 20 (48.78) 7 (35.00) 13 (65.00) .
1+ 21 (51.22) 10 (47.62) 11 (52.38) .
On average how many pN0 colon cancer patients do you see each month? 0.499
<5 28 (68.29) 13 (46.43) 15 (53.57) .
5+ 13 (31.71) 4 (30.77) 9 (69.23) .
Perceptions about Diagnostic/Prognostic Testing
Belief in accuracy of histopathology 0.742
Not Agree 14 (34.15) 5 (35.71) 9 (64.29) .
Agree 27 (65.85) 12 (44.44) 15 (55.56) .
Belief in accuracy of GUY2C testing 0.012
Not Agree 17 (41.46) 3 (17.65) 14 (82.35) .
Agree 24 (58.54) 14 (58.33) 10 (41.67) .
Belief in accuracy of combined histopathology and GUCY2C testing 0.128
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interpreting molecular test results. In other reports,
physicians who have limited familiarity with molecu-
lar diagnostic testing have expressed uncertainty
about their capacity to interpret and explain test
results to their patients, and, as a consequence, may
be more reluctant to support the use of such tests
in practice [4, 6, 7].
It is important to mention that the generalizability of
findings reported here might be limited for several rea-
sons. First, the survey response rate among eligible
Table 3 Univariable associations of physician readiness to act on genomic risk assessment (GUCY2C) for pN0 colon cancer Patients
(Continued)
Not Agree 4 (9.76) 4 (100.0) .
Agree 37 (90.24) 17 (45.95) 20 (54.05) .
Belief in need for a more accurate prognostic test for pN0 colon cancer patients 1.000
Not Agree 2 (4.88) 1 (50.00) 1 (50.00) .
Agree 39 (95.12) 16 (41.03) 23 (58.97) .
Belief that current staging methods are not accurate for pN0 colon cancer patients 0.062
Not Agree 17 (41.46) 4 (23.53) 13 (76.47) .
Agree 24 (58.54) 13 (54.17) 11 (45.83) .
Accuracy of histopathology alone 0.861
(missing/unknown) 1 (.) 0 (.) 1 (.) .
Very Accurate 6 (15.00) 2 (33.33) 4 (66.67) .
Somewhat Accurate 31 (77.50) 14 (45.16) 17 (54.84) .
Not Accurate 3 (7.50) 1 (33.33) 2 (66.67) .
Don’t Know 0 (0.0) 0 (0.0) 0 (0.0)
Accuracy of GUCY2C testing alone 0.179
(missing/unknown) 2 (.) 0 (.) 2 (.) .
Very Accurate 6 (15.38) 5 (83.33) 1 (16.67) .
Somewhat Accurate 22 (56.41) 9 (40.91) 13 (59.09) .
Not Accurate 3 (7.69) 1 (33.33) 2 (66.67) .
Don’t Know 8 (20.51) 2 (25.00) 6 (75.00) .
Accuracy of combined histopathology and GUCY2C testing 0.084
(missing/unknown) 1 (.) 0 (.) 1 (.) .
Very Accurate 25 (62.50) 14 (56.00) 11 (44.00) .
Somewhat Accurate 11 (27.50) 2 (18.18) 9 (81.82) .
Not Accurate 0 (0.0) 0 (0.0) 0 (0.0)
Don’t Know 4 (10.00) 1 (25.00) 3 (75.00) .
Perceptions about Treatment
Stress from uncertainty in decision making about treatment for pN0 colon cancer patients (scale) 0.216
Not Agree (<=3) 22 (53.66) 7 (31.82) 15 (68.18) .
Agree (>3) 19 (46.34) 10 (52.63) 9 (47.37) .
Belief that treatment decision making for pN0 colon cancer patients is easy 0.499
Not Agree 13 (31.71) 4 (30.77) 9 (69.23) .
Agree 28 (68.29) 13 (46.43) 15 (53.57) .
Confidence in treatment decision making for pN0 colon cancer patients 0.729
Not Agree 12 (29.27) 4 (33.33) 8 (66.67) .
Agree 29 (70.73) 13 (44.83) 16 (55.17) .
Belief that treatment choice for pN0 colon cancer patients is clear 0.025
Not Agree 19 (46.34) 4 (21.05) 15 (78.95) .
Agree 22 (53.66) 13 (59.09) 9 (40.91) .
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physicians was less than 50 %. Therefore, survey responses
may not be representative of physicians who care for pa-
tients diagnosed with early-stage colon cancer. In addition,
the survey was administered to physicians in one geo-
graphic area; and, perceptions related to molecular diag-
nostic testing may reflect those held by practitioners in
this region. In addition, the number of physicians who
completed the survey is small, thus, findings from our
analyses may be spurious. It is also the case that we col-
lected data on only physician perceptions and receptivity
to the use of only one molecular test for a specified set of
cancer patients. Findings may vary if another type of test
had been presented and a different set of patients were
referenced. Social desirability in survey response may be
another challenge to generalizabilty, as respondents could
have been motivated to provide what they may viewed as
a “correct” response to survey items.
Conclusion
Health care institutions and groups committed to devel-
oping state-of-the-art practice guidelines are placing
greater emphasis on physician education about the use
of laboratory-developed molecular tests in personalized
medicine [21]. Research on a national cohort of clini-
cians is needed to identify factors that influence phys-
ician uptake of molecular testing for cancer patients and
to determine the impact of test results on clinical rec-
ommendations that are made. Furthermore, research
should also focus attention on assessing patient out-
comes that result from using these new evidence-based
diagnostic and prognostic methods.
In the future, there will be a steady increase in predict-
ive molecular testing in cancer care. The adoption of
such testing will be influenced by a variety of factors, in-
cluding organizational factors and provider characteris-
tics and perceptions. Teng et al. have concluded that
evidence suggests that the adoption of molecular testing
in routine care is most likely to take place when this
service is performed as a laboratory test commonly
performed at the time of diagnosis, rather than requiring
a discretionary order for testing, and when payers
routinely reimburse testing [22]. It is expected that on-
going efforts to include molecular diagnostic testing in
clinical guidelines will add momentum to this process
[23]. Findings reported in the current study highlight the
need to address physician educational and decision sup-
port needs to advance the use of molecular testing.
Furthermore, the movement towards patient-centered
care highlights the importance of physician-patient shared
decision-making about diagnostic testing and treatment.
Decision support interventions that are designed to pro-
vide patients with information, elicit values and prefer-
ences related to treatment options, and facilitate shared
decision making must also be integrated into clinical prac-
tice. Centers of excellence in medical care must lead the
way by deploying effective methods for overcoming struc-
tural obstacles, operational barriers, and individual limita-
tions to molecular test uptake. This effort should include
support for shared decision making in health systems and
the prospective assessment of clinical outcomes.
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